Search results for "veri"

showing 10 items of 2149 documents

Effectiveness of opioid rotation in the control of cancer pain: The ROTODOL Study

2014

Objective: To assess the effectiveness of opioid rotation (OR) to manage cancer pain. To describe the adverse events (AEs) associated with OR. Setting: Thirty-nine tertiary hospital services.Patients: Sixty-seven oncological patients with cancer-related pain treated at outpatient clinics.Intervention: Prospective multicenter study. Pain intensity was scored using a Numerical Rating Scale (NRS) of 0-10. Average pain (AP) intensity in the last 24 hours, breakthrough pain (BTP), and the number of episodes of BTP on the days before and 1 week after OR were assessed. The pre-OR and post-OR opioid were recorded. The presence and intensity of any AEs occurring after OR were also recorded.Results: …

AdultMaleTime FactorsSeverity of Illness IndexDrug Administration ScheduleTertiary Care CentersBasal (phylogenetics)AnalgèsicsRating scaleOpioid rotationNeoplasmsHumansMedicineOutpatient clinicPharmacology (medical)Prospective StudiesAdverse effectAgedPain MeasurementAged 80 and overDrug Substitutionbusiness.industryBreakthrough PainGeneral MedicineMiddle AgedIntensity (physics)Analgesics OpioidTreatment OutcomeAnesthesiology and Pain MedicineOpioidSpainAnesthesiaFemaleChronic PainOpiDolor oncològicbusinessCancer painmedicine.drugJournal of Opioid Management
researchProduct

Efficacy and safety of topiramate in migraine prophylaxis: an open controlled randomized study comparing Sincronil and topamax formulations.

2013

AIM: Topiramate is a small molecule widely used for the treatment of epilepsy, migraine, bipolar disorders and alcoholism, and its availability as a generic formulation could significantly reduce the National Health Service expenditure. A generic formulation, available in Italy under the trademark Sincronil, recently showed superimposable blood levels, after oral administration to healthy volunteers, with the reference formulation. In the present study we report the results of an open label, parallel group, randomized, controlled study performed to evaluate the efficacy, tolerability and impact on disability of two different formulations of topiramate (Sincronil and Topamax) in patients wit…

AdultMaleTime Factorstopiramate migraineAdolescentChemistry PharmaceuticalMigraine DisordersFructoseMiddle AgedSeverity of Illness IndexYoung AdultTreatment OutcomeItalyTopiramateDrugs GenericHumansFemaleAgedCentral Nervous System Agents
researchProduct

Characteristics of tinnitus with or without hearing loss: Clinical observations in Sicilian tinnitus patients

2010

Objective: To analyze the clinical characteristics of tinnitus both in normal hearing subjects and in patients with hearing loss. Methods: The study considered 312 tinnitus sufferers, 176 males and 136 females, ranging from 21 to 83 years of age, who were referred to the Audiology Section of the Department of Bio-technology of Palermo University. The following parameters were considered: age, sex, hearing threshold, tinnitus laterality, tinnitus duration, tinnitus measurements and subjective disturbance caused by tinnitus. The sample was divided into two groups: Group 1 (G1) subjects with normal hearing; Group 2 (G2) subjects with hearing loss. Results: Among the patients considered, 115 ha…

AdultMaleTinnitumedicine.medical_specialtyTime FactorsHearing lossHearing Loss SensorineuralLoudness PerceptionAudiologySeverity of Illness IndexTinnitusYoung AdultAge DistributionNormal hearingSensationotorhinolaryngologic diseasesmedicineHumansIn patientSex DistributionPitch PerceptionSicilyAgedAged 80 and overAbsolute threshold of hearingbusiness.industrySignificant differenceGeneral MedicineHearing lossMiddle Agedmedicine.diseaseSettore MED/32 - AudiologiaSettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyLateralityQuality of LifeSurgerySensorineural hearing lossFemalemedicine.symptombusinessTinnitusStress Psychological
researchProduct

Exploratory Factor Analysis and Validation Study of the Lifetime Severity Index for Cocaine, Spanish Version (LSI-C-Spanish)

2007

The purpose of the study was to do an exploratory factor analysis and to examine the criterion-related and discriminant validity of the Lifetime Severity Index for Cocaine (LSI-C), Spanish version. A sample of 171 outpatients from 10 drug centers in Spain participated in the study. We conducted the factor analysis with orthogonal rotation and examined correlations between the LSI-C total score and criterion variables as well as the score obtained by a quality of life measure. The factor analysis revealed 2 principal factors that explain 65.8% of the variance. Lower LSI-C scores were associated with taking medication, receiving social help, using cocaine fewer than 30 times during the previo…

AdultMaleValidation studymedicine.medical_specialtyIndex (economics)AdolescentPsychometricsPsychometricsPopulation DynamicsSeverity of Illness IndexCocaine-Related DisordersQuality of lifeSeverity of illnessmedicineHumansPsychiatryLanguagePsychiatric Status Rating ScalesDiscriminant validityReproducibility of ResultsSpanish versionMiddle AgedExploratory factor analysisHospitalizationPsychiatry and Mental healthSpainQuality of LifeFemaleSubstance Abuse Treatment CentersDrug OverdoseFactor Analysis StatisticalPsychologyDemographyJournal of Nervous & Mental Disease
researchProduct

Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and s…

2015

The mobilization pattern and functionality of endothelial progenitor cells after an acute ischemic event remain largely unknown. The aim of our study was to characterize and compare the short- and long-term mobilization of endothelial progenitor cells and circulating endothelial cells after acute myocardial infarction or atherothrombotic stroke, and to determine the relationship between these cell counts and plasma concentrations of vascular cell adhesion molecule (VCAM-1) and Von Willebrand factor (VWF) as surrogate markers of endothelial damage and inflammation. In addition, we assessed whether endothelial progenitor cells behave like functional endothelial cells. We included 150 patients…

AdultMaleVascular Endothelial Growth Factor ACD31medicine.medical_specialtyTime FactorsMyocardial InfarctionCD34Vascular Cell Adhesion Molecule-1Cell CountInflammationSeverity of Illness IndexEndothelial progenitor cellImmunophenotypingchemistry.chemical_compoundVasculogenesisRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesProgenitor cellMolecular BiologyCells CulturedAgedEndothelial Progenitor Cellsbusiness.industryEndothelial CellsMiddle AgedStrokeVascular endothelial growth factorPhenotypeEndocrinologychemistryCase-Control StudiesCardiologyCD146Femalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Molecular and Cellular Cardiology
researchProduct

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

2004

Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index (PMI). Some pain was reported by 74% of patients (42% mild, 24% …

AdultMalecancer painCancer Researchmedicine.medical_specialtyLung NeoplasmsAnalgesicPainBone NeoplasmsSeverity of Illness Indexlaw.inventionClinicalPain Management IndexRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungInternal medicineEpidemiologySeverity of illnessPrevalencemedicineHumansPain ManagementAgedPain MeasurementRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGuidelineanalgesicMiddle AgedClinical triallung cancerItalyOncologyanalgesicsQuality of LifePhysical therapyFemalebusinessCancer painBritish Journal of Cancer
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct

Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I

2018

The quantification of enzyme activity in the patient treated with enzyme replacement therapy (ERT) has been suggested as a tool for dosage individualization, so we conducted a study to evaluate the relationship between glucocerebrosidase activity and clinical response in patients with Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity measurement in patients' leucocytes were studied: enzyme activity at 15 min. post-infusion (Act75 ) reflects the amount of enzyme that is distributed in the body post-ERT infusion, and accumulated glucocerebrosidase activity …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyDiseaseToxicologySeverity of Illness IndexGastroenterology03 medical and health sciencesGlucocerebrosidase activity0302 clinical medicineStatistical significanceInternal medicineLeukocytesHumansMedicineEnzyme Replacement TherapyIn patientProspective Studies030212 general & internal medicineInverse correlationAgedEnzyme AssaysPharmacologyGaucher DiseaseDose-Response Relationship Drugbiologybusiness.industryArea under the curvenutritional and metabolic diseasesGeneral MedicineEnzyme replacement therapyMiddle AgedEnzyme assayTreatment Outcome030220 oncology & carcinogenesisbiology.proteinGlucosylceramidaseFemalebusinessBiomarkersFollow-Up StudiesBasic & Clinical Pharmacology & Toxicology
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

Allelic variants of IL1R1gene associate with severe hand osteoarthritis

2010

Background In search for genes predisposing to osteoarthritis (OA), several genome wide scans have provided evidence for linkage on 2q. In this study we targeted a 470 kb region on 2q11.2 presenting the locus with most evidence for linkage to severe OA of distal interphalangeal joints (DIP) in our genome wide scan families. Methods We genotyped 32 single nucleotide polymorphisms (SNPs) in this 470 kb region comprising six genes belonging to the interleukin 1 superfamily and monitored for association with individual SNPs and SNP haplotypes among severe familial hand OA cases (material extended from our previous linkage study; n = 134), unrelated end-stage bilateral primary knee OA cases (n =…

AdultMalelcsh:Internal medicineLinkage disequilibriumLINKAGE DISEQUILIBRIUMlcsh:QH426-470Hand JointsNF-KAPPA-BSingle-nucleotide polymorphismLocus (genetics)KNEE OSTEOARTHRITISBiologyRADIOGRAPHIC SIGNSPolymorphism Single NucleotideSeverity of Illness IndexGenomeCHROMOSOME 2QINTERLEUKIN-1 RECEPTOR ANTAGONIST03 medical and health sciences0302 clinical medicineOsteoarthritisGeneticsHumansSNPGenetic Predisposition to DiseaseGenetics(clinical)Allelelcsh:RC31-1245GeneAllelesPOLYMORPHISMSGenetics (clinical)AgedHAPLOTYPE RECONSTRUCTION030304 developmental biologyReceptors Interleukin-1 Type I030203 arthritis & rheumatologyGenetics0303 health sciencesHaplotypeCLUSTERMiddle Aged314 Health sciences3. Good healthlcsh:GeneticsCase-Control StudiesDISC DEGENERATIONFemaleResearch ArticleBMC Medical Genetics
researchProduct